MAGELLAN LONGEVITY
HomeNutraceuticals & Cellular Energizers › Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)

Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)

Written and medically reviewed by , physiatrist · Last reviewed · How we grade
In one paragraph

Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield), graded Moderate-evidence on Magellan — a small randomized crossover trial found the combination lowered the inflammatory marker CRP by about 23% versus placebo. Genuinely mixed: the NIH GAIT trial was negative overall while the MOVES trial found the combination comparable to celecoxib, and recent meta-analyses are modestly favorable.

Source: Ann Rheum Dis 2015, PMID 25589511 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high

Nutraceuticals & Cellular Energizers24 PubMed citations
$13.79 typical listed price — check the live price on Amazon
View Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield) on Amazon ↗   Open in the Magellan store →

What it is

Osteo Bi-Flex Triple Strength is an oral joint-health supplement whose principal ingredients are glucosamine and chondroitin sulfate, two natural constituents of cartilage. Glucosamine is a building block for the glycosaminoglycans that make up cartilage, and chondroitin sulfate contributes to cartilage's resistance to compression; both are marketed to support joint comfort and function in osteoarthritis. They are sold together as dietary supplements in the United States and, in some countries, as prescription symptomatic slow-acting drugs for osteoarthritis (SYSADOAs). Glucosamine is available as either glucosamine sulfate or glucosamine hydrochloride, a distinction that appears to matter in clinical studies.

Its role in longevity

Evidence on glucosamine and chondroitin for osteoarthritis is large but genuinely mixed. The pivotal NIH-funded GAIT trial and several network meta-analyses found no clinically meaningful benefit over placebo in the overall population, whereas the MOVES trial reported the combination was as effective as celecoxib for severe knee pain, recent meta-analyses report modest symptom benefits, and 3-year trials of glucosamine sulfate suggest it may slow joint-space narrowing. A small randomized crossover trial found the combination lowered the inflammatory marker CRP by about 23% versus placebo. Both agents are consistently reported as safe and well tolerated. Large observational cohorts link regular glucosamine use to lower all-cause and cardiovascular mortality and fewer cardiovascular events, but a published 2022 analysis argues these associations reflect healthy-user selection bias, so they are hypothesis-generating, not proof of lifespan benefit. This evidence describes the glucosamine and chondroitin compounds and their formulations in general, not this specific commercial product.

Watch: the 495,000-person cohort behind glucosamine's grade — and why observational data isn't proof. 37 sec.

The research

Peer-reviewed studies on the active compound — citations link to PubMed.

“Chondroitin sulfate plus glucosamine matched celecoxib, cutting WOMAC pain ~50% at 6 months with a good safety profile.”
Ann Rheum Dis 2015 · PMID 25589511
“For patients with moderate-to-severe knee pain, the glucosamine–chondroitin combination produced a significantly higher response than placebo (79.2% vs 54.3%, P=0.002).”
N Engl J Med 2006 · PMID 16495392
“Both doses of 5-Loxin produced clinically and statistically significant improvements in osteoarthritis pain and function, with reduced cartilage-degrading MMP-3.”
Arthritis Res Ther 2008 · PMID 18667054
“Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.”
J Orthop Surg Res 2018 · PMID 29980200
“Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.”
Arch Orthop Trauma Surg 2023 · PMID 35024906
“The benefit was small to moderate with an 8 point greater improvement in pain (range 0 to 100) and a 2 point greater improvement in Lequesne's index (range 0 to 24), both seeming clinically meaningful.”
Cochrane Database Syst Rev 2015 · PMID 25629804

Research describes the active mechanism and is not a claim about this specific product.

Educational information, not medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if pregnant, nursing, or taking medication.

More in Nutraceuticals & Cellular Energizers

Omega-3 EPA/DHA Fish Oil

Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…

Creatine Monohydrate

Across meta-analyses and randomized trials, creatine monohydrate combined with…

Astaxanthin Softgels

In humans, randomized trials and meta-analyses most consistently show that astaxanthin…

Zinc Picolinate

Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…

See all Nutraceuticals & Cellular Energizers →

FAQ

Does Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield) have scientific evidence?

Yes — its active compound is linked to 24 peer-reviewed studies, summarized and cited above.

Where can I buy Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)?

You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.

Is Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield) safe?

Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.